Praxis Precision Medicines, Inc. (PRAX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Marcio Silva De'Souza M.B.A. | President, CEO & Director | 1.18M | -- | 1979 |
| Mr. Timothy Edwin Kelly | CFO & Treasurer | 691.58k | -- | 1974 |
| Mr. Alex Nemiroff J.D. | General Counsel & Secretary | 577.34k | -- | 1980 |
| Dr. Steven Petrou B.Sc. (Hons.), Ph.D. | Co-Founder & Chief Scientific Officer | -- | -- | -- |
| Lauren Mastrocola | VP of Finance & Principal Accounting Officer | -- | -- | -- |
| Dr. Karl Hansen Ph.D. | Chief Technical Operations Officer | -- | -- | -- |
| Alex Kane | VP of Investor Relations & Corporate Communications | -- | -- | -- |
| Ms. Kelly McCue | Chief People Officer | -- | -- | -- |
| Ms. Alyssa J. S. Wyant | Chief Regulatory & Quality Officer | -- | -- | 1975 |
| Ms. Megan T. Sniecinski | Chief Business Officer | -- | -- | 1982 |
Praxis Precision Medicines, Inc.
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 82
Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Corporate Governance
Upcoming Events
November 5, 2024 at 1:30 PM UTC - November 11, 2024 at 1:30 PM UTC
Praxis Precision Medicines, Inc. Earnings Date